SPINAL MUSCULAR ATROPHY
FDA approves Genentech’s treatment for spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
FDA approves Genentech’s treatment for spinal muscular atrophy (SMA) in adults and children 2 months of age and older.